Nutrition & Lifestyle
    Retatrutide

    Retatrutide Meal Plan: 7-Day High-Protein Guide

    A retatrutide meal plan needs to prioritize protein density and nutrient value in smaller portions. With appetite dramatically reduced by triple-agonist therapy (Jastreboff et al., NEJM 2023), every meal must work harder to deliver the protein, vitamins, and minerals your body needs to preserve muscle mass, maintain energy, and support healthy weight loss. This 7-day plan provides approximately 80-100g protein daily in GLP-1-friendly portions.

    Published: April 3, 202614 min read

    Meal planning on GLP-1 medications is fundamentally different from traditional diet planning. You are not trying to restrict yourself -- the medication handles appetite suppression. Instead, you are trying to maximize nutrition from whatever limited amount of food you can comfortably eat. This requires a protein-first approach, small frequent meals, GI-friendly food choices, and strategic meal prep to ensure healthy options are always available.

    Nutritional Guidance Notice

    Retatrutide is not FDA-approved for any indication. This meal plan is a general guide -- individual needs vary. Consult a registered dietitian for personalized nutrition. Compounded semaglutide ($99/mo) and tirzepatide ($125/mo) are available now.

    Meal Plan Principles

    • Protein first: Eat protein before vegetables, then carbohydrates last
    • Small portions: 4-6 small meals rather than 3 large ones
    • Hydrate between meals: Avoid drinking large amounts during meals (reduces stomach capacity for food)
    • Prep ahead: Have protein-rich options ready when appetite allows eating

    Sample Day: Monday

    Breakfast (25g protein): 2 scrambled eggs with spinach + 1/4 cup cottage cheese

    Mid-morning snack (15g protein): Greek yogurt (plain, 2%) with a handful of berries

    Lunch (25g protein): 4 oz grilled chicken breast over mixed greens with cucumber, tomato, and olive oil dressing

    Afternoon snack (10g protein): 1 oz cheese with 4-5 whole grain crackers

    Dinner (25g protein): 4 oz baked salmon with roasted asparagus and 1/3 cup quinoa

    Total: ~1,200 calories, ~100g protein. Adjust portions based on appetite and tolerance.

    Sample Day: Wednesday

    Breakfast (20g protein): Protein smoothie -- 1 scoop whey protein, 1/2 banana, handful of spinach, almond milk

    Mid-morning (15g protein): 2 hard-boiled eggs

    Lunch (25g protein): Turkey and avocado lettuce wraps (3-4 oz deli turkey in large lettuce leaves)

    Afternoon (15g protein): 1/2 cup cottage cheese with sliced peach

    Dinner (25g protein): 4 oz lean ground turkey stir-fry with bell peppers, broccoli, and soy-ginger sauce over cauliflower rice

    Total: ~1,150 calories, ~100g protein.

    Sample Day: Saturday

    Breakfast (25g protein): Veggie omelet -- 2 eggs + 1 egg white with mushrooms, peppers, and 1 oz feta cheese

    Mid-morning (20g protein): Protein shake with almond butter

    Lunch (20g protein): Tuna salad (4 oz tuna, light mayo, celery) on whole grain toast

    Afternoon (10g protein): Handful of almonds + string cheese

    Dinner (25g protein): 4 oz grilled shrimp with zucchini noodles and marinara sauce

    Total: ~1,250 calories, ~100g protein.

    Adapting the Plan to Your Needs

    This plan is a starting framework. On days when appetite is especially low (common after dose increases), focus on protein shakes and easily digestible options. On higher-appetite days, you can increase portions slightly. The goal is consistent protein intake of at least 60-80g daily, regardless of total caloric intake. For full weekly variety, see our grocery shopping guide and meal prep strategies.

    Medical Disclaimer

    This article is for informational purposes only and does not constitute medical or nutritional advice. Retatrutide is not FDA-approved for any indication. Individual nutritional needs vary. Consult a registered dietitian for personalized meal planning, especially if you have diabetes, kidney disease, food allergies, or other conditions requiring dietary modifications.

    Start Your Transformation With Expert Support

    Compounded semaglutide from $99/mo. Compounded tirzepatide from $125/mo. Provider-supervised weight loss.

    View Treatment Options

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial, the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial, the highest published mean weight reduction for any GLP-1-class agent in obesity to date., Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg., Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial, the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: January 8, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Just recieved my order today. I placed order Monday afternoon and arrived this afternoon. Everything packaged great, clear instructions to follow. The customer service was excellent. I have tried other companies, but this is the most affordable by far. I am almost at my goal weight.

    Outcome: Next-day arrival; most affordable tried; near goal weight

    - Raquel R.Facebook
    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    - Robyn Lynn CurtisFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1), NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Step-by-step retatrutide injection: 6-day half-life, once-weekly dosing, site rotation, and how to time shots for fewer side effects and better weight loss results.

    What to expect in your first month on retatrutide: realistic weight loss expectations, side effects, appetite changes, and tips for maximizing early results during the dose titration phase.

    Should you exercise on retatrutide injection day? Practical guidelines for timing workouts around your weekly injection, managing side effects, and maintaining exercise consistency.

    How much walking should you do on retatrutide? Evidence-based walking guidelines for GLP-1 weight loss patients, including step targets, intensity recommendations, and tips for managing side effects.

    Start your GLP-1 journey, from $99/mo

    Get Started